Author: Alisha GC
B-cell maturation antigen (BCMA), also known as TNFRSF17, is a critical survival receptor expressed mainly on plasma cells and malignant plasma cells in multiple myeloma. As a member of the tumor necrosis factor receptor (TNFR) superfamily, BCMA plays an important role in regulating plasma cell proliferation, differentiation and survival through interaction with its ligands BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). Activation of BCMA triggers downstream signaling pathways including NF-κB, PI3K–AKT and MAPK, which promote tumor growth and resistance to apoptosis. Due to its restricted expression pattern and central role in plasma cell biology, BCMA has emerged as one of the most promising therapeutic targets in multiple myeloma. This review explores the molecular structure of BCMA, its physiological role in B cell development, signaling mechanisms, and the therapeutic strategies designed to target BCMA in cancer immunotherapy.
Multiple myeloma is a haematological malignancy characterized by uncontrolled proliferation of plasma cells in the bone marrow. These malignant plasma cells produce abnormal immunoglobulins and interfere with normal hematopoiesis.
Recent advances in cancer immunotherapy have identified BCMA (B cell maturation antigen) as a key molecular target in multiple myeloma.
BCMA is uniquely suited for targeted therapy because it shows:
-
High expression on malignant plasma cells
-
Minimal expression in normal tissue
-
A critical role in plasma cell survival signaling
These properties have made BCMA the focus of several innovative therapies, including:
-
Bispecific antibodies
-
CAR-T cell therapy
-
Antibody-drug conjugates
To understand BCMA signaling pathway is essential for developing effective treatments and overcoming therapeutic resistance.
BCMA (TNFRSF17) is one type III transmembrane receptor which belongs to the tumor necrosis factor receptor superfamily.
The receptor contains several structural components:
Extracellular domain
This domain binds the ligands BAFF and APRIL.
Transmembrane region
Anchors the receptor in the plasma membrane.
Intracellular cytoplasmic domain
Interacts with adapter proteins that initiate downstream signaling cascades.
Unlike many other TNF receptors, BCMA has a relatively short cytoplasmic tail, but still efficiently recruits signaling molecules that regulate plasma cell survival.
BCMA expression is tightly regulated during B cell development.
BCMA is primarily expressed in:
Importantly, the BCMA is not significantly expressed on hematopoietic stem cells or most non-immune tissueswhich minimizes off-target toxicity when used as a therapeutic target.
This restricted expression pattern makes BCMA particularly suitable for targeted immunotherapy.
BCMA signaling is activated by two primary ligands:
BAFF (B-cell activating factor)
BAFF is a cytokine that belongs to the TNF family and is produced by:
-
Monocytes
-
Dendritic cells
-
Power cells
BAFF regulates B cell maturation and survival.
APRIL (A proliferation-inducing ligand)
APRIL is another cytokine in the TNF family that binds BCMA with higher affinity than BAFF.
APRIL is produced by:
APRIL–BCMA interaction is particularly important in multiple myeloma progressionas it promotes tumor cell survival in the bone marrow microenvironment.
Upon ligand binding, BCMA recruits adapter proteins that initiate several intracellular signaling pathways.
Important signal components include TNF receptor-associated factors (TRAFs).
These adapter proteins activate several downstream pathways.
NF-κB signaling pathway
One of the most important pathways activated by BCMA is NF-κB signaling.
Activation of NF-kB leads to:
NF-κB signaling plays a central role in the pathogenesis of multiple myeloma.
PI3K–AKT signaling pathway
The PI3K–AKT pathway regulates cellular metabolism, proliferation and survival.
Activation of this pathway results in:
This pathway contributes to therapy resistance in multiple myeloma.
MAPK signaling cascade
The MAPK pathway regulates cell growth and differentiation.
Activation leads to:
Together, these signaling pathways create a powerful survival network for malignant plasma cells.
BCMA signaling contributes to multiple aspects of myeloma biology.
Tumor cell survival
Activation of BCMA promotes anti-apoptotic signaling, allowing tumor cells to avoid programmed cell death.
Interaction with the bone marrow microenvironment
Myeloma cells interact with stromal cells, osteoclasts and immune cells in the bone marrow niche.
These cells produce APRIL and BAFFwhich continuously activates BCMA signaling.
Immune evasion
BCMA signaling may contribute to immune evasion by altering cytokine production and immune cell recruitment.
BCMA can be cleaved from the cell surface by γ-secretaseproduces soluble BCMA (sBCMA).
Elevated sBCMA levels are associated with:
-
Higher tumor burden
-
Disease progression
-
Poor prognosis
sBCMA is increasingly used as a biomarker for monitoring treatment response in multiple myeloma.
Because of its critical biological role, BCMA has become one of the most important targets in modern multiple myeloma therapy.
Three major therapeutic approaches target BCMA.
Bispecific antibodies
Bispecific antibodies simultaneously bind BCMA on tumor cells and CD3 on T cells.
This interaction redirects cytotoxic T lymphocytes towards malignant plasma cells.
Examples include:
These therapies represent an important off-the-shelf immunotherapy option.
CAR-T cell therapy
CAR-T therapy involves genetically modifying a patient’s T cells to recognize BCMA.
Once infused, these engineered T cells can:
Examples include:
Antibody-drug conjugates
Antibody-drug conjugates deliver chemotherapy directly to BCMA-expressing tumor cells.
The antibody binds BCMA, and the internalized drug payload induces tumor cell death.
Example:
Despite impressive clinical responses, resistance can develop.
Important mechanisms include:
Loss of BCMA antigen
Tumor cells can reduce or eliminate BCMA expression.
T cell exhaustion
Chronic immune activation can lead to dysfunctional T cells with reduced cytotoxic capacity.
Immunosuppressive microenvironment
Bone marrow stromal cells and regulatory immune cells can inhibit anti-tumor immune responses.
New research aims to improve BCMA-targeted therapies through:
-
Dual-antigen targeted antibodies
-
Combination immunotherapy
-
Improved CAR-T cell engineering
-
Personalized treatment strategies
These innovations may further improve outcomes for multiple myeloma patients.
BCMA plays a central role in plasma cell survival and multiple myeloma progression through activation of key signaling pathways including NF-κB, PI3K–AKT and MAPK. Its restricted expression pattern and biological significance make BCMA an ideal therapeutic target. Recent advances in immunotherapy—including bispecific antibodies, CAR-T cell therapy, and antibody-drug conjugates—have transformed the treatment landscape for patients with relapsed or refractory multiple myeloma. Continued research into BCMA biology and signaling will be essential to overcome resistance mechanisms and improve long-term clinical outcomes.
Q1. What does BCMA stand for?
BCMA stands for B-cell maturation antigen, a receptor mainly expressed on plasma cells.
Q2. Why is BCMA important in multiple myeloma?
BCMA promotes plasma cell survival and proliferation through activation of NF-κB and PI3K – AKT signaling pathways.
Q3. What therapies target BCMA?
Major BCMA therapies include bispecific antibodies, CAR-T cell therapy, and antibody-drug conjugates.
Q4. What is soluble BCMA?
Soluble BCMA is a circulating form of BCMA released from the cell surface and can be used as a biomarker for disease monitoring.
Q5. Why is BCMA considered an ideal therapeutic target?
BCMA is highly expressed on malignant plasma cells but minimally expressed in normal tissue, reducing off-target toxicity.
